OakChart

Optimi Health Corp

OPTHHealthcare·Drug Manufacturers - Specialty & Generic·Canada·Nano·NASD·Nov 11 • 11:22 AM ET

2.27+0.01 (0.67%)
2026-11-11 17:23 CET
Market cap
12.91 USD m
Revenue, TTM
0.10 USD m
Net income, TTM
-1.74 USD m
Free cash flow, TTM
-2.07 USD m
EPS diluted, TTM
-0.40
P/E
-
Compare

Price

OPTH against its 20, 50 and 200-day averages
2050200earnings
2.004.006.008.001.1M2.2MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26OPTHclose 2.2720-day 2.7850-day 3.83200-day 5.442.2752w low

74.3% under the 52-week high of 8.84 on 17 Feb 2026. 52-week low 1.90 on 4 Nov 2026. Last 15 sessions, 89.5% high to low

Profile

OPTH
52-week range, 5% of the way up
1.908.84

Optimi Health Corp. functions as an end-to-end GMP manufacturer and supplier of psychedelic substances. It offers formulation, active pharmaceutical ingredients (APIs), and drug product manufacturing from preclinical stages to analysis and commercial distribution and It also offers botanical psilocybin and MDMA. The company was founded on May 27, 2020 and is headquartered in Squamish, Canada.

IPOMay 20, 2026
Beta1.39
ATR, 14d0.33
Rel volume0.84
Short float0.47%
Insider own18.98%
Inst own10.24%

Snapshot

6 groups

Valuation

Index-
Market Cap13.01M
Enterprise Value7.43M
Income-
Sales-
Book/sh2.17
Cash/sh1.61
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees-
IPOMay 20, 2026

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.05
P/C1.41
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio1.69
Current Ratio1.73
Debt/Eq0.29
LT Debt/Eq0.01
Option/ShortNo / Yes

Earnings

EPS (ttm)-
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y27.91% -72.14%
Sales past 3/5Y68.99% -
EPS Y/Y TTM34.45%
Sales Y/Y TTM-
EPS Q/Q-842.19%
Sales Q/Q137.27%
EarningsAug 14 BMO
EPS/Sales Surpr.-43.14% -34.88%

Ownership

Insider Own18.98%
Insider Trans0.00%
Inst Own10.24%
Inst Trans14.57%
ROA-
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-18.34%
SMA50-40.70%
SMA200-58.25%
Trades-

Technical

Shs Outstand5.73M
Shs Float4.64M
Short Float0.47%
Short Ratio0.51
Short Interest0.02M
52W High8.84 -74.32%
52W Low1.90 19.47%
Volatility15.20% 13.69%
ATR (14)0.33
RSI (14)29.25
Beta1.39
Rel Volume0.84
Avg Volume42.03K
Volume11,348

Performance

Perf Week2.71%
Perf Month-35.14%
Perf Quarter-53.00%
Perf Half Y-66.99%
Perf YTD-66.87%
Perf Year-68.15%
Perf 3Y-35.17%
Perf 5Y-84.77%
Perf 10Y-
Recom-
Target Price-
Prev Close2.26
Price2.27
Change %0.67%

Peers

Mkt cap
TickerCompanyMkt cap
PBMPsyence Biomedical Ltd12.40M
OGIOrganigram Global Inc122.59M
CRONCronos Group Inc1.25B
TLRYTilray Brands Inc375.18M
CMPSCompass Pathways Plc ADR1.32B
CMNDClearmind Medicine Inc2.82M
GHRSGH Research PLC1.34B
ENVBEnveric Biosciences Inc6.58M
SILOSILO Pharma Inc3.13M
SNDLSNDL Inc341.87M

Held by

AUM
TickerCompanyAUM
PSILAdvisorShares Psychedelics ETFAUM: 43.26M

News

latest 14 of 70
  • Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
  • Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
  • Optimi Health Establishes Optimi Australia Pty Ltd as Dedicated Distribution and Business Development Entity (GlobeNewswire)
  • Optimi Health Completes MDMA Production for Phase 3 PTSD Trial in Canada, MAPS Trial in Israel and Commercial Supply in Australia (GlobeNewswire)
  • Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive) -9.70%
  • Loading…
  • Optimi Health to Present at the ThinkEquity Conference (GlobeNewswire)
  • Optimi Health Appoints Melanie Pump to Board of Directors (GlobeNewswire)
  • Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply (GlobeNewswire)
  • Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer (GlobeNewswire)
  • Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
  • Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder (GlobeNewswire)
  • Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder (GlobeNewswire)
  • Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-08-14-0.404-0.282-0.100.161
2026Q22026-06-01-0.254-0.261-0.3600.130.131
2026Q12026-02-25-0.348--0.3460.00--
2026Q4---0.127--0.191
2027Q1---0.127--0.201
2027Q2---0.113--0.211
2027Q3---0.113--0.211
2027Q4---0.099--0.231

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
No annual earnings.

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-09-131000.190.190.19
2026Q4S2026-08-141010.190.190.19
2026Q4S2026-06-301010.190.190.19
2026Q4S2026-06-021000.200.200.20
2026Q4S2026-05-261000.200.200.20
2026Q4E2026-09-13100-0.13-0.13-0.13
2026Q4E2026-08-14110-0.13-0.13-0.13
2026Q4E2026-06-30110-0.13-0.13-0.13
2026Q4E2026-06-02100-0.13-0.13-0.13
2026Q4E2026-05-26100-0.13-0.13-0.13
2026Q3S2026-06-301010.160.160.16
2026Q3S2026-06-021000.160.160.16
2026Q3S2026-05-261000.160.160.16
2026Q3E2026-06-30110-0.28-0.28-0.28

Estimate history

EPS, annual-0.055-2.044-2.215-1.328-1.486-0.83
Period202020212022202320242025
EPS, quarterly-0.365-0.398-0.4-0.285-0.043-0.203-0.346-0.36-0.404
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q1 '26Q2 '26Q3 '26
Sales, annual000.0630.1340.2860.305
Period202020212022202320242025
Sales, quarterly0.0610.0910.0420.1660.0430.14200.0730.101
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q1 '26Q2 '26Q3 '26
Shares, annual2.292.3292.6982.9013.1553.2215.726
Period202020212022202320242025MRQ
Shares, quarterly2.9693.0883.1553.1553.2213.2213.2213.2265.726
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Total Revenue0.100.300.290.130.060.000.00
Cost of Goods Sold Incl. D&A0.411.792.081.892.110.040.00
Gross Profit-0.31-1.48-1.80-1.75-2.05-0.04-0.00
Selling, General and Administrative Excl. Other1.241.762.412.283.744.750.12
Research and Development0.080.250.110.110.100.19-
Other Operating Expense0.000.000.000.000.000.000.00
Operating Income-1.54-3.24-4.21-4.03-5.78-4.79-0.12
Interest Expense0.200.380.320.030.020.020.00
Unusual Expense0.00-0.95-0.09-0.120.000.000.00
Net Income Before Taxes-1.74-2.65-4.44-3.85-5.75-4.76-0.13
Income Taxes0.000.000.000.000.000.000.00
Consolidated Net Income-1.74-2.65-4.44-3.85-5.75-4.76-0.13
Net Income From Continuing Operations-1.74-2.65-4.44-3.85-5.75-4.76-0.13
Net Income-1.74-2.65-4.44-3.85-5.75-4.76-0.13
EPS (Recurring)-0.40-1.04-1.51-1.36-2.21-2.04-0.05
EPS (Basic, Before Extraordinaries)-0.40-0.83-1.49-1.33-2.21-2.04-0.05
EPS (Diluted)-0.40-0.83-1.49-1.33-2.21-2.04-0.05
EBITDA-1.38-2.56-3.57-3.49-5.55-4.75-0.12
Non-Operating Income (Expense)0.000.010.000.090.050.040.00
Other After Tax Adjustments0.000.000.000.000.000.000.00
Stock Option Compensation Expense0.030.030.040.120.791.00-
Price To Sales Ratio-87.1155.5288.65278.33--
Gross Margin--486.44-626.83-1,306.01-3,240.18--
Operating Margin--1,062.29-1,469.45-3,004.28-9,155.15--
Net Margin--870.75-1,548.25-2,868.54-9,106.89--
Shares Outstanding5.733.223.162.902.702.332.29
Market Capitalization12.9112.9117.2211.5617.5634.9433.10

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q32025Q22025Q12024Q42024Q3
Total Revenue0.100.070.000.140.040.170.040.09
Cost of Goods Sold Incl. D&A0.410.450.190.350.410.440.480.23
Gross Profit-0.31-0.38-0.19-0.21-0.36-0.27-0.43-0.14
Selling, General and Administrative Excl. Other1.240.610.730.370.330.550.710.63
Research and Development0.080.030.030.000.000.140.100.13
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-1.54-0.99-0.92-0.58-0.69-0.83-1.15-0.77
Interest Expense0.200.170.200.080.080.080.100.07
Unusual Expense0.000.000.000.00-0.630.000.020.00
Net Income Before Taxes-1.74-1.16-1.11-0.66-0.14-0.90-1.26-1.19
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-1.74-1.16-1.11-0.66-0.14-0.90-1.26-1.19
Net Income From Continuing Operations-1.74-1.16-1.11-0.66-0.14-0.90-1.26-1.19
Net Income-1.74-1.16-1.11-0.66-0.14-0.90-1.26-1.19
EPS (Recurring)-0.40-0.36-0.35-0.20-0.18-0.29-0.40-0.40
EPS (Basic, Before Extraordinaries)-0.40-0.36-0.35-0.20-0.04-0.29-0.40-0.40
EPS (Diluted)-0.40-0.36-0.35-0.20-0.04-0.29-0.40-0.40
EBITDA-1.38-0.82-0.73-0.41-0.53-0.66-0.96-0.61
Non-Operating Income (Expense)0.000.000.000.000.000.01-0.00-0.01
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.030.080.000.000.030.000.000.00
Price To Sales Ratio---30.6142.8938.3061.9088.50
Gross Margin-302.64-519.16--145.49-849.53-164.34-1,022.09-156.02
Operating Margin-1,522.61-1,363.74--406.23-1,614.99-497.73-2,706.42-851.20
Net Margin-1,715.01-1,599.88--462.00-320.64-541.03-2,978.28-1,311.62
Shares Outstanding5.733.233.223.223.223.163.163.09
Market Capitalization12.9120.2322.0710.8215.1415.1117.2221.39

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY
Cash & Short Term Investments0.820.080.991.379.813.38
Short Term Receivables0.070.090.120.070.150.06
Inventories0.220.660.580.190.000.00
Other Current Assets0.200.080.100.131.330.01
Total Current Assets1.310.911.801.7711.293.46
Net Property, Plant & Equipment9.039.8510.3910.477.031.14
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.590.010.010.010.200.02
Total Assets10.9310.7712.2012.2418.524.62
Short Term Debt Incl. Current Port. of LT Debt4.570.730.030.060.080.02
Accounts Payable0.850.550.790.000.000.00
Other Current Liabilities0.671.090.380.471.690.54
Total Current Liabilities6.102.381.190.531.770.56
Long Term Debt0.111.301.240.050.120.10
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities6.213.682.430.581.890.66
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity4.727.099.7711.6616.633.96
Total Shareholders Equity4.727.099.7711.6616.633.96
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity4.727.099.7711.6616.633.96
Total Liabilities & Stockholders Equity10.9310.7712.2012.2418.524.62
Book Value Per Share1.472.253.374.327.141.73
Tangible Book Value Per Share1.472.253.374.327.141.73
Price to Book Ratio1.042.431.081.512.101.75
Return on Assets-24.47-38.62-31.52-37.41-41.14-
Return on Equity-44.96-52.62-35.94-40.68-46.24-
Return on Invested Capital-54.90-52.87-34.99-49.14-28.41-3.10
Quick Ratio0.180.111.022.976.396.15
Current Ratio0.220.381.513.336.396.15

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Net Income-1.72-2.65-4.44-3.85-5.75-4.76-0.13
Depreciation0.160.680.640.540.230.040.00
Other Funds (Non Cash)0.05-0.800.100.030.801.140.00
Funds from Operations-1.50-2.77-3.70-3.28-4.72-3.59-0.12
Extraordinary Item0.000.000.000.000.000.000.00
Changes in Working Capital-0.550.890.560.611.14-1.180.02
Cash from Operating Activities-2.05-1.88-3.15-2.67-3.58-4.76-0.11
Capital Expenditures-0.02-0.06-0.11-0.60-5.60-3.90-0.56
Net Assets From Acquisitions0.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.010.000.000.00
Purchase or Sale of Investments0.000.000.000.003.13-3.160.00
Purchase of Investments0.000.000.000.000.00-3.160.00
Sale Or Maturity of Investments0.000.000.000.003.130.000.00
Other Uses0.000.00-0.00-0.000.00-0.200.00
Other Sources0.000.000.000.070.000.000.00
Cash from Investing Activities-0.02-0.06-0.11-0.52-2.47-7.27-0.56
Cash Dividends Paid0.000.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.000.00
Change in Capital Stock12.150.281.641.371.0215.174.04
Repurchase of Common Pref Stock0.000.000.000.000.000.000.00
Sale of Common Pref Stock12.150.281.641.371.0215.174.04
Proceedsfrom Stock Options12.150.281.501.371.0215.164.04
Issuance or Reduction of Debt, Net-0.722.470.731.480.000.000.00
Change in Long Term Debt0.002.470.731.480.000.000.00
Issuance of Long Term Debt0.002.470.731.480.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.02-0.030.000.000.000.00-0.05
Other Financing Activities Uses0.02-0.030.000.000.000.00-0.05
Cash from Financing Activities11.442.692.352.790.9315.133.99
Net Change in Cash9.370.74-0.91-0.40-5.123.093.32
Free Cash Flow-2.07-1.94-3.26-3.27-9.18-8.67-0.67
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q32025Q22025Q1
Cash & Short Term Investments9.210.080.360.060.040.06
Short Term Receivables0.030.030.090.190.060.07
Inventories0.210.220.230.480.470.44
Other Current Assets0.390.080.140.040.020.05
Total Current Assets9.840.400.810.770.580.63
Net Property, Plant & Equipment8.378.668.979.268.949.10
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.010.620.600.330.010.01
Total Assets18.239.6810.3910.369.539.74
Short Term Debt Incl. Current Port. of LT Debt3.534.604.660.730.700.70
Accounts Payable0.951.091.021.090.660.61
Other Current Liabilities1.221.350.930.830.901.18
Total Current Liabilities5.707.046.622.652.262.49
Long Term Debt0.100.100.111.361.271.24
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.670.000.00
Total Liabilities5.807.156.734.683.533.73
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity12.432.543.665.686.016.01
Total Shareholders Equity12.432.543.665.686.016.01
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity12.432.543.665.686.016.01
Total Liabilities & Stockholders Equity18.239.6810.3910.369.539.74
Book Value Per Share2.170.791.141.761.861.90
Tangible Book Value Per Share2.170.791.141.761.861.90
Price to Book Ratio1.047.986.031.912.522.52
Return on Assets----27.66-33.62-40.92
Return on Equity----43.87-48.79-58.29
Return on Invested Capital-13.86-43.99-29.56-9.31-1.88-12.41
Quick Ratio1.690.030.090.110.050.08
Current Ratio1.730.060.120.290.260.25

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q32025Q22025Q1
Net Income-1.72-1.18-1.11-0.69-0.11-0.90
Depreciation0.160.170.190.180.150.16
Other Funds (Non Cash)0.050.110.03-0.18-0.570.04
Funds from Operations-1.50-0.90-0.90-0.70-0.53-0.70
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.550.650.440.070.480.48
Cash from Operating Activities-2.05-0.25-0.46-0.63-0.05-0.22
Capital Expenditures-0.02-0.01-0.00-0.000.01-0.02
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.02-0.01-0.00-0.000.01-0.02
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock12.150.000.000.020.040.23
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock12.150.000.000.020.040.23
Proceedsfrom Stock Options12.150.000.000.020.040.23
Issuance or Reduction of Debt, Net-0.720.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.02-0.020.000.640.000.00
Other Financing Activities Uses0.02-0.020.00-0.020.000.00
Cash from Financing Activities11.44-0.03-0.010.650.030.22
Net Change in Cash9.37-0.29-0.470.02-0.02-0.02
Free Cash Flow-2.07-0.26-0.46-0.63-0.05-0.24

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.47%0.0M4.6M39.40K
2026-10-150.55%0.0M4.6M41.32K
2026-09-300.64%0.0M4.6M50.03K
2026-09-150.44%0.0M4.6M73.02K
2026-08-310.21%0.0M4.6M89.81K
2026-08-140.38%0.0M4.6M143.05K
2026-07-310.45%0.0M4.6M138.85K
2026-07-151.62%0.1M4.5M134.75K
2026-06-301.48%0.1M4.5M120.68K
2026-06-150.95%0.0M4.5M92.11K
2026-05-290.94%0.0M3.4M61.35K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-26SEC
2026-10-206-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-20SEC
2026-10-076-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-07SEC
2026-10-05SCHEDULE 13G/ASEC
2026-09-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-29SEC
2026-09-236-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-23SEC
2026-09-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-22SEC
2026-09-166-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-16SEC
2026-09-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-10SEC
2026-09-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-08SEC
2026-08-27424B3SEC
2026-08-276-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-26SEC
2026-08-25EFFECTEffectiveness filing by commission orderSEC
2026-08-17F-1Registration statement for certain foreign private issuersSEC
2026-08-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-14SEC
2026-08-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-08-076-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-07SEC
2026-07-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-28SEC
2026-07-206-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-20SEC
2026-07-07S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-06-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-29SEC
2026-06-166-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-16SEC
2026-06-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-10SEC
2026-06-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-08SEC
2026-06-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-02SEC
2026-06-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-01SEC
2026-05-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-29SEC
2026-05-27SCHEDULE 13GSEC
2026-05-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-26SEC
2026-05-20424B4SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
AdvisorShares Investments LLC4.55%
Yorkville Advisors Global, LP3.54%
Mariner, LLC2.17%
StoneX Group Inc.0.19%
TWO SIGMA SECURITIES, LLC0.19%
UBS Group AG0.04%
ROYAL BANK OF CANADA0.03%
NATIONAL BANK OF CANADA /FI/0.01%
TD Waterhouse Canada Inc.0.01%
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO0.00%

Funds

Fund% owned
AdvisorShares Psychedelics ETF1.83%

OakChart. OPTH. Cached 15 minutes.

Some panels did not load: ratings, insider.